Study of ALK-001 on the Progression of Stargardt Disease | MicrobiomeTrials← Back to trialsNCT07419334
Study of ALK-001 on the Progression of Stargardt Disease
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-06Est. Completion: 2029-10
Enrollment target: 230 participants Locations- Associated Retina Consultants, Phoenix, Arizona, United States
- Vitreo Retinal Associates, Gainesville, Florida, United States
- Erie Retina Research, Erie, Pennsylvania, United States
- Retina Foundation of the Southwest, Dallas, Texas, United States
Other microbiome trials you might be interested in
Stargardt-Like Macular Dystrophy
Background:
STDG3 is an inherited eye disease. Currently there is no treatment for STDG3. Past studies of STDG3 have la…
Bethesda, United StatesEst. completion Jul 16, 2028
Retinal DegenerationABCA4-Related Retinopathies
Background:
\- The ABCA4 gene contains a blueprint for the ABCA4 protein. When this protein is absent or faulty (such a…
Bethesda, United States
ABCA4 RetinopathyStargardt DiseaseRetinal DystrophyRetinal Degeneration
Background:
ABCA4 retinopathy is a genetic disease in which the ABCA4 protein is absent or faulty. It can cause waste m…
Bethesda, United StatesEst. completion Feb 2, 2028